TB-201

N/A

Report date: 2024/09/04 17:31:03

Base Information

Drug NameTB-201

Drug Alias NameTB-201

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionAnti-MUC1

TargetsMucin-1

Therapy Area/IndicationsSolid tumoursTriple Negative Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTherabest INC Peptron Inc

China Registration ClassN/A

Develop Information

Active CompaniesTherabest INC Peptron Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursTriple Negative Breast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A